SUBSCRIBE
SUBSCRIBE

Immunic Therapeutics

IN THE PRESS
Press Releases
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
September 4, 2024
 · 
10 min read
Press Releases
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September 2024
August 28, 2024
 · 
8 min read
Press Releases
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
August 1, 2024
 · 
5 min read
Press Releases
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
July 24, 2024
 · 
7 min read
Pharm Country
Immunic to Participate in Industry and Scientific Conferences in June 2024
May 28, 2024
 · 
5 min read
Business
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
 · 
14 min read
Pharm Country
Immunic to Participate in Investor and Scientific Conferences in May 2024
May 6, 2024
 · 
6 min read
Business
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
May 1, 2024
 · 
5 min read
Drug Development
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
April 30, 2024
 · 
10 min read
Pharm Country
Immunic to Host MS R&D Day and Participate in Investor Conferences in April 2024
April 4, 2024
 · 
5 min read
Load More
JOBS